Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.440
-0.090 (-2.55%)
At close: Jun 27, 2025, 4:00 PM
3.450
+0.010 (0.29%)
After-hours: Jun 27, 2025, 4:34 PM EDT
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 56 employees as of December 31, 2024. The number of employees decreased by 19 or -25.33% compared to the previous year.
Employees
56
Change (1Y)
-19
Growth (1Y)
-25.33%
Revenue / Employee
n/a
Profits / Employee
-$2,490,857
Market Cap
294.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56 | -19 | -25.33% |
| Dec 31, 2023 | 75 | 5 | 7.14% |
| Dec 31, 2022 | 70 | 11 | 18.64% |
| Dec 31, 2021 | 59 | 20 | 51.28% |
| Dec 31, 2020 | 39 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVIR News
- 4 days ago - Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 3 months ago - Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - GlobeNewsWire